Beta Bionics Faces Securities Class Action Over iLet Safety Concerns
News related to:Beta Bionics, Inc · 1 min read
SAN FRANCISCO, Sept. 17, 2026 /CourierPR/ -- Beta Bionics, Inc., a company developing automated insulin delivery systems, is facing a securities class action lawsuit. The lawsuit, filed by the national shareholders' rights firm Hagens Berman, seeks to represent investors who purchased or otherwise acquired shares of the company's common stock between July 30, 2025, and February 24, 2026. The class period spans a critical period during which the company faced significant regulatory scrutiny and subsequent revelations about its iLet automated insulin delivery system.
On October 28, 2025, Beta Bionics' management discussed their receipt of a Form 483 from the FDA following an inspection of the iLet manufacturing process. The management downplayed the inspection, stating it was "not unusual in our industry" and that their new complaint handling system met or exceeded the agency's expectations.
The complaint alleges that Beta Bionics concealed thousands of iLet safety complaints, including numerous life-threatening hypoglycemic events, and failed to investigate or report these events to the FDA as required. By February 24, 2026, when the FDA published its January 28, 2026, WARNING LETTER to CEO Saint, investors learned the truth. The FDA cited significant violations, including the company's failure to adequately analyze quality data, implement corrective and preventative actions for device malfunctions leading to serious adverse health outcomes, and failure to report information to the FDA no later than 30 calendar days after receiving information that reasonably suggested a device may have caused or contributed to a death or serious injury.
Hagens Berman encourages Beta Bionics investors who suffered substantial losses to submit their losses now. The firm is also seeking whistleblowers with non-public information regarding Beta Bionics.
Hagens Berman has a history of securing significant recoveries for its clients, having achieved more than $2.9 billion in this area of law. The firm's commitment to corporate accountability and investor protection is evident in its ongoing investigation and legal action against Beta Bionics.